CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Benitec Biopharma Inc. - BNTC CFD

    6.8029
    0.73%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.1242
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 0.01
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 6.8529
    Open* 6.8129
    1-Year Change* 2979.97%
    Day's Range* 6.3429 - 7.0529
    52 wk Range 1.86-9.01
    Average Volume (10 days) 5,360.00
    Average Volume (3 months) 189.68K
    Market Cap 7.57M
    P/E Ratio -100.00K
    Shares Outstanding 2.57M
    Revenue 75.00K
    EPS -11.60
    Dividend (Yield %) N/A
    Beta 0.88
    Next Earnings Date Feb 12, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 19, 2024 6.8029 -0.0300 -0.44% 6.8329 7.0529 6.3429
    Apr 18, 2024 6.8529 1.6100 30.71% 5.2429 7.3929 5.0729
    Apr 17, 2024 4.7929 0.0000 0.00% 4.7929 4.8929 4.7129
    Apr 16, 2024 4.7429 0.0300 0.64% 4.7129 4.8429 4.5629
    Apr 15, 2024 4.7429 -0.4400 -8.49% 5.1829 5.4729 4.6429
    Apr 12, 2024 5.3929 -0.4200 -7.23% 5.8129 6.1829 5.1829
    Apr 11, 2024 6.1229 0.5500 9.87% 5.5729 6.2329 5.5729
    Apr 10, 2024 5.9429 0.3600 6.45% 5.5829 5.9429 5.5129
    Apr 9, 2024 5.8929 0.5200 9.68% 5.3729 5.8929 5.3329
    Apr 8, 2024 5.5929 0.2400 4.48% 5.3529 5.5929 5.3529
    Apr 5, 2024 5.4529 0.1200 2.25% 5.3329 5.4729 5.3329
    Apr 4, 2024 5.4129 -0.0800 -1.46% 5.4929 5.6029 5.2729
    Apr 3, 2024 5.4829 0.4500 8.94% 5.0329 5.6929 5.0329
    Apr 2, 2024 5.1329 0.1000 1.99% 5.0329 5.3029 5.0329
    Apr 1, 2024 5.0829 -0.0300 -0.59% 5.1129 5.3229 5.0329
    Mar 28, 2024 5.0929 -0.0500 -0.97% 5.1429 5.1429 4.9729
    Mar 27, 2024 5.0729 0.2200 4.53% 4.8529 5.0729 4.7429
    Mar 26, 2024 4.8929 0.1500 3.16% 4.7429 5.0229 4.7429
    Mar 25, 2024 4.9529 0.2100 4.43% 4.7429 5.1329 4.7429
    Mar 22, 2024 4.8429 -0.3000 -5.83% 5.1429 5.2429 4.7529

    Benitec Biopharma Inc. Events

    Time (UTC) Country Event
    Monday, May 13, 2024

    Time (UTC)

    12:00

    Country

    US

    Event

    Q3 2024 Benitec Biopharma Inc Earnings Release
    Q3 2024 Benitec Biopharma Inc Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, September 19, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q4 2024 Benitec Biopharma Inc Earnings Release
    Q4 2024 Benitec Biopharma Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2023 2022 2021 2020 2019
    Total revenue 0.075 0.073 0.059 0.102 10.7
    Revenue 0.075 0.073 0.059 0.102 10.7
    Cost of Revenue, Total 0 0.009 0.123 -0.185 0.392501
    Gross Profit 0.075 0.064 -0.064 0.287 10.3075
    Total Operating Expense 19.156 17.927 13.655 8.383 8.66337
    Selling/General/Admin. Expenses, Total 6.382 6.646 6.512 5.567 6.12791
    Research & Development 12.774 11.272 7.02 3.001 2.00053
    Unusual Expense (Income)
    Operating Income -19.081 -17.854 -13.596 -8.281 2.03662
    Interest Income (Expense), Net Non-Operating -0.451 -0.275 -0.323 -0.027 0.607764
    Net Income Before Taxes -19.562 -18.208 -13.882 -8.274 2.63858
    Net Income After Taxes -19.562 -18.208 -13.882 -8.274 2.63858
    Net Income Before Extra. Items -19.562 -18.208 -13.882 -8.274 2.63858
    Net Income -19.562 -18.208 -13.882 -8.274 2.63858
    Income Available to Common Excl. Extra. Items -19.562 -18.208 -13.882 -8.274 2.63858
    Income Available to Common Incl. Extra. Items -19.562 -18.208 -13.882 -8.274 2.63858
    Diluted Net Income -19.562 -18.208 -13.882 -8.274 2.63858
    Diluted Weighted Average Shares 1.38582 0.48069 0.25266 0.06007 10.079
    Diluted EPS Excluding Extraordinary Items -14.1159 -37.879 -54.9442 -137.747 0.26179
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -14.1159 -37.879 -54.9442 -137.747 0.262363
    Depreciation / Amortization 0.142435
    Gain (Loss) on Sale of Assets -0.005801
    Other, Net -0.03 -0.079 0.037 0.034
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.007 0.054 0.014 0 0
    Revenue 0.007 0.054 0.014 0 0
    Cost of Revenue, Total 0.009
    Gross Profit -0.009
    Total Operating Expense 4.557 4.395 5.624 4.58 4.738
    Selling/General/Admin. Expenses, Total 1.371 1.228 1.863 1.92 1.553
    Research & Development 3.186 3.167 3.761 2.66 3.176
    Operating Income -4.55 -4.341 -5.61 -4.58 -4.738
    Interest Income (Expense), Net Non-Operating -0.031 -0.056 0.149 -0.513 -0.279
    Other, Net -0.08 0 0.05 -0.05
    Net Income Before Taxes -4.661 -4.397 -5.411 -5.093 -5.067
    Net Income After Taxes -4.661 -4.397 -5.411 -5.093 -5.067
    Net Income Before Extra. Items -4.661 -4.397 -5.411 -5.093 -5.067
    Net Income -4.661 -4.397 -5.411 -5.093 -5.067
    Income Available to Common Excl. Extra. Items -4.661 -4.397 -5.411 -5.093 -5.067
    Income Available to Common Incl. Extra. Items -4.661 -4.397 -5.411 -5.093 -5.067
    Diluted Net Income -4.661 -4.397 -5.411 -5.093 -5.067
    Diluted Weighted Average Shares 1.645 1.64595 1.62118 0.63853 0.48069
    Diluted EPS Excluding Extraordinary Items -2.83343 -2.6714 -3.33769 -7.9761 -10.5411
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -2.83343 -2.6714 -3.33769 -7.9761 -10.5411
    Other Operating Expenses, Total
    • Annual
    • Quarterly
    2023 2022 2021 2020 2019
    Total Current Assets 3.729 4.82 20.608 10.809 17.0192
    Cash and Short Term Investments 2.477 4.062 19.769 9.801 14.3775
    Cash & Equivalents 2.477 4.062 0 4.57 14.2623
    Total Receivables, Net 0.055 0.003 0.025 0.059 2.30122
    Accounts Receivable - Trade, Net 0.055 0.003 0.025 0.059 2.30122
    Other Current Assets, Total 0.014 0.019 0.032 0.088
    Total Assets 4.464 5.973 21.379 11.587 17.4539
    Property/Plant/Equipment, Total - Net 0.613 0.993 0.577 0.769 0.426388
    Total Current Liabilities 3.978 2.532 1.369 1.136 2.39668
    Accounts Payable 1.14 0.422 0.274 0.282 1.33707
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.069 0.071 0.174 0.25 0.932325
    Total Liabilities 4.262 3.091 1.369 1.349 2.39668
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0.284 0.559 0 0.213 0
    Total Equity 0.202 2.882 20.01 10.238 15.0572
    Common Stock 0.00016 0.001 0.001 0.001 104.425
    Retained Earnings (Accumulated Deficit) -167.889 -148.327 -130.119 -116.636 -88.4353
    Total Liabilities & Shareholders’ Equity 4.464 5.973 21.379 11.587 17.4539
    Total Common Shares Outstanding 1.64595 0.48069 0.48069 0.06519 15.1185
    Short Term Investments 0.115188
    Long Term Investments 0.008273
    Prepaid Expenses 1.183 0.736 0.782 0.861 0.340474
    Property/Plant/Equipment, Total - Gross 1.931 2.175 1.595 1.565 1.03415
    Accumulated Depreciation, Total -1.318 -1.182 -1.018 -0.796 -0.607762
    Accrued Expenses 2.769 2.039 0.921 0.604 0.12728
    Other Equity, Total -0.83016 -1.245 -1.455 -1.953 -0.932325
    Cash 19.769 5.231
    Other Long Term Assets, Total 0.122 0.16 0.194 0.009
    Additional Paid-In Capital 168.921 152.453 151.583 128.826
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total Current Assets 3.729 7.395 10.975 17.081 4.82
    Cash and Short Term Investments 2.477 6.551 10.537 16.534 4.062
    Cash
    Cash & Equivalents 2.477 6.551 10.537 16.534 4.062
    Total Receivables, Net 0.055 0.056 0.068 0.003 0.003
    Accounts Receivable - Trade, Net 0.055 0.056 0.068 0.003 0.003
    Prepaid Expenses 1.183 0.774 0.356 0.531 0.736
    Total Assets 4.464 8.22 11.905 18.115 5.973
    Property/Plant/Equipment, Total - Net 0.613 0.695 0.789 0.89 0.993
    Property/Plant/Equipment, Total - Gross 1.931 1.992 2.054 2.114 2.175
    Accumulated Depreciation, Total -1.318 -1.297 -1.265 -1.224 -1.182
    Other Long Term Assets, Total 0.122 0.13 0.141 0.144 0.16
    Total Current Liabilities 3.978 3.153 2.489 3.011 2.532
    Accounts Payable 1.14 0.635 0.531 0.608 0.422
    Accrued Expenses 2.769 2.482 1.917 2.275 2.039
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.069 0.036 0.041 0.128 0.071
    Total Liabilities 4.262 3.507 2.911 3.502 3.091
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0.284 0.354 0.422 0.491 0.559
    Total Equity 0.202 4.713 8.994 14.613 2.882
    Common Stock 0.00016 0.003 0.003 0.003 0.001
    Additional Paid-In Capital 168.921 168.791 168.72 168.768 152.453
    Retained Earnings (Accumulated Deficit) -167.889 -163.228 -158.831 -153.42 -148.327
    Other Equity, Total -0.83016 -0.853 -0.898 -0.738 -1.245
    Total Liabilities & Shareholders’ Equity 4.464 8.22 11.905 18.115 5.973
    Total Common Shares Outstanding 1.64595 1.64595 1.64595 1.51821 0.48069
    Other Current Assets, Total 0.014 0.014 0.014 0.013 0.019
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Cash From Operating Activities -15.899 -12.832 -7.535 3.8949 -6.51301
    Cash Receipts 11.7466 0.23009
    Cash Payments -10.7012 -9.64117
    Changes in Working Capital -15.899 -12.832 -7.535 2.84952 2.89807
    Cash From Investing Activities -0.013 -0.221 -0.094 -0.37905 -0.097755
    Capital Expenditures -0.013 -0.221 -0.095 -0.38304 -0.055195
    Cash From Financing Activities 0 22.522 1.77 0 5.65715
    Financing Cash Flow Items 0 -3.228 -0.48 0 -0.208145
    Issuance (Retirement) of Stock, Net 0 25.75 2.25 0 5.8653
    Foreign Exchange Effects 0.204 0.499 -0.058 0.690935 0.09576
    Net Change in Cash -15.708 9.968 -5.917 4.20679 -0.85785
    Other Investing Cash Flow Items, Total 0 0.001 0.00399 -0.04256
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Cash From Operating Activities -13.917 -9.888 -4.045 -15.899 -11.044
    Changes in Working Capital -13.917 -9.888 -4.045 -15.899 -11.044
    Cash From Investing Activities 0 0 -0.013 0
    Capital Expenditures -0.013 0
    Other Investing Cash Flow Items, Total 0 0
    Cash From Financing Activities 16.015 16.015 16.015 0 0
    Financing Cash Flow Items -1.869 -1.869 -1.869 0 0
    Issuance (Retirement) of Stock, Net 17.884 17.884 17.884 0 0
    Foreign Exchange Effects 0.391 0.348 0.501 0.204 -0.095
    Net Change in Cash 2.489 6.475 12.471 -15.708 -11.139

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Benitec Biopharma Inc. Company profile

    About Benitec Biopharma Inc

    Benitec Biopharma Inc is an Australia-based biotechnology company. The Company is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The Company's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The Company's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.

    Financial summary

    BRIEF: For the six months ended 31 December 2021, Benitec Biopharma Inc revenues decreased 55% to $25K. Net loss increased 65% to $9.9M. Revenues reflect Licensing revenue segment decrease from $56K to $0K. Higher net loss reflects Research and development - Balancing val increase from $1.9M to $5.8M (expense), Stock-based Compensation in SGA increase from $105K to $349K (expense).

    Equity composition

    FY'05 is being restated for change in reporting GAAP to IFRS.04/2009, Rights Issue, 1 new share for every 3.142 shares held @ AUD .03 (Factor:1.000000). 04/2011, Rights Issue, 4 new shares for every 5 shares held @ AUD 0.02 (Factor:1.235330). 07/2013, 1-for-25 Reverse Stock split.

    Industry: Biotechnology & Medical Research (NEC)

    3940 Trust Way
    HAYWARD
    CALIFORNIA 94545
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    People also watch

    XRP/USD

    0.52 Price
    +2.100% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    US100

    17,037.80 Price
    -1.980% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    BTC/USD

    63,921.35 Price
    -0.280% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    ETH/USD

    3,057.33 Price
    -0.800% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading